The structural differences found among the three groups, and specificallythosebetweenlong-termlithium-treatedandunmedicatedBD-Ipatients,indicateincreasedlimbicstructurevolumesinlithium-treatedpatients.
limited data are available about the neurobiological reasons why they should be continued or discontinued in euthymic patients, and abouttheirneuroanatomicaleffectsontheneuralcircuitsofemotion regulation. [3] [4] [5] A number of studies and meta-analyses have reported cerebral structural alterations in patients with BD. Compared to healthy subjects,BD-Ipatientsonaveragehavediminishedhippocampalgray matter 6 and,asdemonstratedbyarecentmeta-analysis,increasedvolumeofthelateralventricles,mainlytherightventricle.
6-9
Additionally, decreasedamygdalavolumehasbeenreportedinadults, 10 children and adolescentswithBD-Iwhencomparedtohealthycontrolsubjects.
11
Moreover, there is evidence of amygdala abnormalities prior to bipolar disorder onset in ultra-high risk patients compared with a healthycontrolgroup. 12 Ithasalsobeenfoundthatthereisadirect relationship between the incidence of manic episodes and frontal cortical volume decrease (dorsolateral prefrontal and inferior frontal cortex) in BD patients. 13 Nevertheless, other studies have reportedeithernodifference 14 orevenincreasedamygdalavolume inBDpatientscomparedwithcontrolsubjects 15 andschizophrenic patients, 16 whichshowsthatchangesinamygdalavolumesarenota universalfinding.
Psychotropic drugs commonly used to treat BD-I, including lithium,havebeenreportedtorevertorattenuatetheseneuroanatomical abnormalities associated with the disorder. 8 An apparent neuroprotectiveeffectoflithiumisassociatedwithincreasedvolumesofsome neuroanatomicalstructureswithinthecortico-limbicneuralcircuit.
17
Baykaraetal.found,asasecondaryoutcome,thatrighthippocampal volumewasincreasedinlithium-treatedyoungpatientswithBDcomparedtotheunmedicatedgroup. 18 Althoughthemechanismofaction of the effects of lithium on brain structures is not fully understood, studies in both humans and animals have provided evidence for its neurotrophicaction.
19
Inadultrodents,lithiumproducesasignificant 25%increaseinnewcellsinthedentategyrus,suggestingthatlithium enhances hippocampal neurogenesis. 20 However, no association has been found between changes in hippocampal anatomy and lithium dosage.
21
Theeffectofmedicationonthesebrainstructuresisnotyetclear andthestudiesconductedtodatehavesomelimitationsconcerning their samples, particularly the exclusion criteria for participation.
9
Experimental groups very often comprise patients who are taking combinationsofpsychotropicmedications,withdifferentsubtypesof BD in the same sample, high psychiatric comorbidity, and unknown personalhistoryoftraumaticbraininjury,substancedependenceand electroconvulsive therapy; and some of the studies have no control group.
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It has been strongly recommended that future studies 
| METHODS

| Subjects
Thestudyparticipantswere32patientsdiagnosedwithBD 
| AcquisitionandprocessingofMRI
| Statisticalanalysis
Thedescriptiveanalysisofthestudyparticipantswasbasedonmeas 
| RESULTS
| Demographicandclinicalvariables
Thethreestudygroups-long-termlithium-treatedBD-Ipatients, unmedicated BD-I patients, and healthy controls -had similar socio-demographic characteristics (education, age and gender)
withnostatisticallysignificantdifferences.Regardingtheclinical variables, both the lithium-treated and the unmedicated groups had an average of 17years of illness duration. The number of manicanddepressiveepisodes,however,wassignificantlylower in the unmedicated group than in the lithium-treated patients (P=.010). No significant differences were found between medicated and unmedicated subjects in HDRS and YMRS scores (Table1).
| Comparisonsbetweengroups
| Comparisonamongthethreegroups
Age-adjusted ANCOVA showed significant differences among the three groups in the volumes of the left amygdala (P=.0003), right amygdala (P=.030), left hippocampus (P=.022), left thalamus (P=.022),rightthalamus(P=.019)andposteriorhalfcorpuscallosum.
Differences in white matter hypointensities were also identified among the three study groups (P=.012), but no significant differences were found in the other brain regions under study (the prefrontalcortex,pallidum,caudate,accumbensandcingulategyrus)or inthevolumeofthelateralventricles(left,P=.053andright,P=.236).
Inthecomparisonofglobalbrainvolume,nosignificantdifferences werefound(P=.546)(Table2).
| Comparisonbetweenlong-termlithiumtreatedandunmedicatedbipolarpatients
Multivariableanalysis ( The patients from the lithium group had a greater number of white matter hypointensities than unmedicated patients. There were no differencesbetweenthetwogroupsinglobalbrainvolume(P=.273) andvolumeofthehippocampusoroftheotherbrainstructuresunder study(Table3).
| Comparisonbetweenlithium-treatedbipolar patientsandcontrolsubjects
Multivariable analysis demonstrated that lithium-treated BD-I patients had significantly larger volumes than control subjects for the left amygdala (P=.025), right amygdala (P=.025), left thalamus (P=.022), right thalamus (P=.020) and left hippocampus (P=.007).
Lithium-treated BD-I patients did not show differences in the volume of the corpus callosum in comparison with the control group.
Thelithiumgrouphadagreaternumberofwhitematterhypointensitiesthanhealthycontrols.Nodifferenceswerereportedbetween thetwogroupsinthevolumeofbasalgangliaoringlobalbrainvolume(P=.499). 
| Correlationbetweenvolumeandserum lithium levels
| DISCUSSION
In the present study, significant differences were found when comparing amygdala, thalamus and hippocampal volumes among lithium-treatedBD-Ipatients,unmedicatedBD-Ipatients,andhealthy controls.Thestudyisuniqueinthatallpatientswerereceivinglongterm lithium monotherapy; this reduced the confounding factors present in other structural neuroimaging studies, in which a high percentage of patients were receiving combined pharmacotherapy.
A volumetric increase was observed in the bilateral amygdala, left hippocampus and bilateral thalamus in lithium-treated BD-I patients comparedtohealthycontrols,databeingadjustedforage,genderand yearsofeducation.WhencomparedwithunmedicatedBD-Ipatients, long-termlithium-treatedBD-Ipatientsdemonstratedsignificantvolume differences in the amygdala and bilateral thalamus, even after multivariableadjustment,whichsuggeststhattheincreaseinthevolume of these structures is due to long-term lithium exposure rather thanaconsequenceoftheunderlyingphysiopathologyofthedisorder.
Our findings are consistent with previous studies and recent meta-analyses which demonstrate that the subgroup of patients whoreceivelithiummayshowincreasedamygdalaandhippocampal volumes.
7,9,17-19,30-33
Lithium treatment has been associated with increased hippocampal head volume, which is not seen with other medicationssuchasvalproateorlamotrigine, 18, 33 andwithincreased volume of the right hippocampus in bipolar adolescents compared to healthy controls. 18 Longitudinal studies show a 4−5% increase in hippocampal volume in lithium-treated patients throughout a 2−4-yearfollow-upperiod.
17,33,34
Ithasbeenreportedthatlithium-treated patientshavelargerbrainvolumes,by7.6%,comparedwithpatients not taking lithium.
7,35
In our results, however, no significant differenceswerefoundinglobalbrainvolumebetweenlong-termlithiumtreatedpatientsandunmedicatedpatients,orinthesizeofthelateral ventriclesinpatientswithBDrelativetocontrols.
A relevant finding, replicated in other studies and reported in several meta-analyses, is the increase in white matter hyperintensities in patients with BD: a 2.5-fold higher probability of white matterhyperintensitieshasbeenreportedforpatientswith BD compared to subjects without the disorder. In this study, 
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